Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient

US6579536B1 · kind B1 · utility

Assignee

• Hexal AG · DE

Inventors

• Richard H. Hirsch · Webster Groves, US
• Martin Wesseling · Barleben, DE
• Thomas Strungmann · Munich, DE

Key dates

• Filing date: Jun 22, 2001
• Grant date: Jun 17, 2003
• Expiry date: Jun 22, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P29/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a solid, sustained-release pharmaceutical composition for oral administration containing tilidine mesylate as active ingredient.